Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate Efficacy and Safety of Sunitinib Therapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment (INMUNOSUN Study)

NCT03066427 is registered in ClinicalTrials.gov with Spanish Oncology Genito-Urinary Group as lead sponsor.

NCT NCT03066427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03066427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate Efficacy and Safety of Sunitinib Therapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment (INMUNOSUN Study)
Lead sponsor
Spanish Oncology Genito-Urinary Group
Phase
Phase 2
Overall status
Completed
Start date
May 10, 2017
Completion date
September 22, 2020
Enrollment
23 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal carcinoma